The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Alpha2-adrenergic agonists for the management of opioid withdrawal
Open accessAbstract
BACKGROUND: Withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment. OBJECTIVES: To assess the effectiveness of interventions involving the use of alpha2-adrenergic agonists compared with placebo, reducing doses of methadone, symptomatic medications, or an alpha2-adrenergic agonist regimen different to the experimental intervention, for the management of the acute phase of opioid withdrawal. Outcomes included the withdrawal syndrome experienced, duration of treatment, occurrence of adverse effects, and completion of treatment. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1946 to November week 2, 2015), EMBASE (January 1985 to November week 2, 2015), PsycINFO (1806 to November week 2, 2015), Web of Science, and reference lists of articles. SELECTION CRITERIA: Randomised controlled trials comparing alpha2-adrenergic agonists (clonidine, lofexidine, guanfacine, tizanidine) with reducing doses of methadone, symptomatic medications or placebo, or comparing different alpha2-adrenergic agonists to modify the signs and symptoms of withdrawal in participants who were opioid dependent. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by The Cochrane Collaboration. MAIN RESULTS: We included 26 randomised controlled trials involving 1728 participants. Six studies compared an alpha2-adrenergic agonist with placebo, 12 with reducing doses of methadone, four with symptomatic medications, and five compared different alpha2-adrenergic agonists. We assessed 10 studies as having a high risk of bias in at least one of the methodological domains that were considered.We found moderate-quality evidence that alpha2-adrenergic agonists were more effective than placebo in ameliorating withdrawal in terms of the likelihood of severe withdrawal (risk ratio (RR) 0.32, 95% confidence interval (CI) 0.18 to 0.57; 3 studies; 148 participants). We found moderate-quality evidence that completion of treatment was significantly more likely with alpha2-adrenergic agonists compared with placebo (RR 1.95, 95% CI 1.34 to 2.84; 3 studies; 148 participants).Peak withdrawal severity may be greater with alpha2-adrenergic agonists than with reducing doses of methadone, as measured by the likelihood of severe withdrawal (RR 1.18, 95% CI 0.81 to 1.73; 5 studies; 340 participants; low quality), and peak withdrawal score (standardised mean difference (SMD) 0.22, 95% CI -0.02 to 0.46; 2 studies; 263 participants; moderate quality), but these differences were not significant and there is no significant difference in severity when considered over the entire duration of the withdrawal episode (SMD 0.13, 95% CI -0.24 to 0.49; 3 studies; 119 participants; moderate quality). The signs and symptoms of withdrawal occurred and resolved earlier with alpha2-adrenergic agonists. The duration of treatment was significantly longer with reducing doses of methadone (SMD -1.07, 95% CI -1.31 to -0.83; 3 studies; 310 participants; low quality). Hypotensive or other adverse effects were significantly more likely with alpha2-adrenergic agonists (RR 1.92, 95% CI 1.19 to 3.10; 6 studies; 464 participants; low quality), but there was no significant difference in rates of completion of withdrawal treatment (RR 0.85, 95% CI 0.69 to 1.05; 9 studies; 659 participants; low quality).There were insufficient data for quantitative comparison of different alpha2-adrenergic agonists. Available data suggest that lofexidine does not reduce blood pressure to the same extent as clonidine, but is otherwise similar to clonidine. AUTHORS' CONCLUSIONS: Clonidine and lofexidine are more effective than placebo for the management of withdrawal from heroin or methadone. We detected no significant difference in efficacy between treatment regimens based on clonidine or lofexidine and those based on reducing doses of methadone over a period of around 10 days, but methadone was associated with fewer adverse effects than clonidine, and lofexidine has a better safety profile than clonidine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Clonidine blocks acute opiate-withdrawal symptoms
Gold, M., Redmond, D. E., & Kleber, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92823-4 · Cited by 710
THALIDOMIDE AND LIMB DEFORMITIES
Millen, J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)90462-2 · Cited by 462
Global statistics on addictive behaviours: 2014 status report
Gowing, L. R., Ali, R. L., Allsop, S., Marsden, J., Turf, E. E., West, R., & Witton, J. (2015) · Addiction · doi:10.1111/add.12899 · Cited by 410
Self-citationOpiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment
Gold, M. S. (1980) · JAMA · doi:10.1001/jama.243.4.343 · Cited by 326
What Can Long‐term Follow‐up Teach us About Relapse and Prevention of Relapse in Addiction?
VAILLANT, G. E. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb03021.x · Cited by 315
Buprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Self-citationThe economic costs of heroin addiction in the United States
Mark, T. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00162-9 · Cited by 271
Lapse, Relapse and Survival among Opiate Addicts after Treatment: A Prospective Follow-up Study
Gossop, M., Green, L., Phillips, G., & Bradley, B. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.3.348 · Cited by 230
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
The Neuroscience of Drug Reward and Addiction
Volkow, N. D., Michaelides, M., & Baler, R. (2019) · Physiological Reviews · doi:10.1152/physrev.00014.2018 · Cited by 863
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making
Naqvi, N. H., & Bechara, A. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0268-7 · Cited by 598
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
Metadata
- Authors
- Gowing, L., Farrell, M., Ali, R., & White, J. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-03
- Volume
- 2016
- Issue
- 5
- Pages
- CD002024-CD002024
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2135387265
- Cited by
- 271
- References
- 80
- FWCI
- 23.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alpha2-adrenergic agonists for the management of opioid withdrawal. https://app.cochat.ai/papers/10.1002/14651858.cd002024.pub5
- The paper
- Gowing, L., Farrell, M., Ali, R., & White, J. M. (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd002024.pub5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.